HK Stock Market Move | HEC CJ PHARM(01558) rose by over 6%, and the high incidence of flu drove up sales of drugs such as oseltamivir.

HEC CJ PHARM (01558) rose more than 6%, rising 6.54% to 9.94 Hong Kong dollars as of press time, with a turnover of 21.0847 million Hong Kong dollars. On the news front, according to the latest data from the Chinese Center for Disease Control and Prevention, the positive rate of influenza virus is continuously increasing, with over 99% being influenza A. Data from Dingdang Kuaiyao shows that in the past month, the sales growth rate of the anti-influenza drugs oseltamivir and peramivir has reached 164%. HEC CJ PHARM is a Chinese pharmaceutical company dedicated to the development, production, and sales of products in the treatment areas of antivirus, endocrine and metabolic diseases, cardiovascular diseases, etc. Its main products include the anti-influenza drug Kawe (oseltamivir phosphate capsules and granules). From the perspective of enterprise sales, in 2023, a total of 27 companies sold oseltamivir preparations in the sample terminal market. Among them, Yichang HEC CJ PHARM ranked first with a 65.01% sales share.